Press Releases
View printer-friendly version |
Back |
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease
|
Nov
27
CARMIEL, Israel,
The meeting will feature a presentation from KOL David G. Warnock, M.D., The Company's management team will provide an update on PRX‑102. PRX‑102 is an investigational, plant cell culture-expressed, and chemically modified stabilized version of, the recombinant alpha-Galactosidase-A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with unique pharmacokinetic parameters. In clinical studies, PRX‑102 has been observed to have a circulatory half-life of approximately 80 hours. The Company designed pegunigalsidase alfa to potentially address the continued unmet clinical need in Fabry patients of continuous disease progression, infusion reactions and immunogenicity. This event is intended for institutional investors, sell-side analysts and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast. Event Details RSVP: https://lop.by/I5X Webcast: https://lop.by/I5Z About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain U.S. Food and Drug Administration ( Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the Protalix's development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease, in phase III clinical trials (BALANCE, BRIDGE and BRIGHT studies); OPRX‑106, an orally delivered anti-inflammatory treatment; and alidornase alfa for the treatment of Cystic Fibrosis, both in phase II clinical trials. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in Forward-Looking Statements To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "expect," "anticipate," "believe," "estimate," "project," "plan," "should" and "intend," and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences are described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law. Investor Contact Media Contact
View original content:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-hosting-key-opinion-leader-meeting-on-prx102-drug-candidate-for-the-treatment-of-fabry-disease-300966025.html SOURCE |